OPK

+ Watchlist + Portfolio

Opko Health, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.46
52-Week Range: $0.98 – $1.73
Market Cap: $1.09B
P/E (TTM): —
EPS (TTM): -0.07
Dividend Yield: —

Advanced Metrics

Price/Book: 0.92
PEG Ratio: 93.65
Return on Equity: -5.88%
Return on Assets: -5.52%
Gross Margin: 19.64%
Operating Margin: -15.31%
Profit Margin: -12.40%
Current Ratio: 3.35
Debt/Equity: 0.34
Total Debt: $398.08M
Free Cash Flow: $54.79M
Revenue Growth: 4.30%
Earnings Growth: —
Enterprise Value: $1.19B

OPK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.00B	$863.50M	$713.14M	$606.88M
Cost of Revenue	$715.98M	$545.37M	$494.63M	$400.94M
Gross Profit	$288.22M	$318.13M	$218.51M	$205.94M
Research & Development	$73.89M	$89.59M	$105.21M	$124.03M
Selling, General & Admin	$372.67M	$300.56M	$304.22M	$223.00M
Operating Expenses	$534.34M	$476.18M	$492.07M	$424.93M
Operating Income	-$246.12M	-$158.06M	-$273.56M	-$218.99M
EBITDA	-$270.81M	-$65.52M	$135.28M	-$41.27M
Pretax Income	-$391.52M	-$184.32M	-$10.36M	-$241.36M
Income Tax	-$63.50M	$4.44M	$42.84M	-$15.71M
Net Income	-$328.40M	-$188.86M	-$53.22M	-$225.68M
Diluted EPS	-0.46	-0.25	-0.08	-0.30
Diluted Shares	719.06M	751.72M	694.02M	751.13M

OPK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$153.19M	$95.88M	$431.94M	$369.07M
Receivables	$148.61M	$130.20M	$152.05M	$126.12M
Inventory	$74.06M	$65.70M	$56.80M	$65.82M
Current Assets	$394.52M	$309.48M	$662.09M	$581.88M
Total Assets	$2.17B	$2.01B	$2.20B	$1.93B
Current Liabilities	$213.48M	$200.05M	$193.10M	$146.68M
Long-Term Debt	$219.47M	$222.03M	$422.18M	$333.71M
Total Debt	$305.55M	$326.56M	$504.44M	$396.78M
Total Liabilities	$605.61M	$622.48M	$834.76M	$663.99M
Retained Earnings	-$1.82B	-$2.01B	-$2.07B	-$2.29B
Shareholders' Equity	$1.56B	$1.39B	$1.37B	$1.27B
Working Capital	$181.04M	$109.42M	$468.99M	$435.20M
Net Debt	$102.87M	$153.45M	$5.27M	—

OPK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$95.19M	-$28.20M	-$183.49M	-$178.54M
Capital Expenditure	-$24.58M	-$16.27M	-$25.01M	-$12.28M
Free Cash Flow	-$119.77M	-$44.47M	-$208.50M	-$190.82M
Depreciation & Amortisation	$108.66M	$105.30M	$98.18M	$91.63M
Stock-Based Compensation	$18.51M	$11.41M	$11.05M	$10.71M
Investing Cash Flow	$91.04M	-$18.20M	$352.21M	$230.30M
Financing Cash Flow	$22.97M	-$11.30M	$184.17M	-$118.06M
Share Repurchases	$0.00	$0.00	-$90.22M	-$47.04M
Net Change in Cash	$18.82M	-$57.70M	$352.89M	-$66.30M

OPK Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$156.81M	$151.67M	$148.45M	$124.20M	$163.58M
Cost of Revenue	$107.41M	$101.78M	$84.42M	$78.44M	$83.56M
Gross Profit	$49.40M	$49.89M	$64.03M	$45.76M	$80.02M
Research & Development	$30.34M	$30.08M	$32.77M	$29.20M	$33.17M
Selling, General & Admin	$59.60M	$53.80M	$50.52M	$48.61M	$52.92M
Operating Expenses	$109.38M	$103.41M	$102.34M	$96.77M	$105.06M
Operating Income	-$59.98M	-$53.52M	-$38.32M	-$51.02M	-$25.04M
EBITDA	-$69.17M	$75.53M	-$13.22M	-$27.82M	$20.39M
Pretax Income	-$162.52M	$41.43M	-$46.90M	-$60.96M	-$13.40M
Income Tax	-$14.08M	$19.80M	-$15.66M	-$6.11M	-$4.98M
Net Income	-$148.44M	$21.63M	-$31.26M	-$54.85M	-$8.42M
Diluted EPS	-0.19	0.03	-0.04	-0.07	-0.01
Diluted Shares	788.01M	779.92M	765.52M	758.88M	755.27M

OPK Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$271.72M	$415.20M	$369.07M	$341.88M	$300.76M
Receivables	$134.58M	$124.38M	$126.12M	$107.62M	$114.91M
Inventory	$66.34M	$64.95M	$65.82M	$64.40M	$61.85M
Current Assets	$583.33M	$627.13M	$581.88M	$535.36M	$500.24M
Total Assets	$1.97B	$2.00B	$1.93B	$1.86B	$1.83B
Current Liabilities	$171.18M	$169.32M	$146.68M	$148.38M	$149.37M
Long-Term Debt	$329.25M	$331.43M	$333.71M	$336.03M	$338.49M
Total Debt	$395.74M	$395.42M	$396.78M	$396.93M	$398.08M
Total Liabilities	$676.09M	$690.02M	$663.99M	$652.19M	$645.29M
Retained Earnings	-$2.28B	-$2.26B	-$2.29B	-$2.35B	-$2.35B
Shareholders' Equity	$1.30B	$1.31B	$1.27B	$1.20B	$1.18B
Working Capital	$412.15M	$457.81M	$435.20M	$386.98M	$350.87M
Net Debt	$71.56M	—	—	$3.79M	$48.29M

OPK Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$83.42M	-$34.65M	-$25.92M	-$19.31M	-$43.50M
Capital Expenditure	-$3.28M	-$3.13M	-$2.67M	-$1.83M	-$3.00M
Free Cash Flow	-$86.70M	-$37.78M	-$28.59M	-$21.14M	-$46.50M
Depreciation & Amortisation	$23.03M	$22.74M	$22.37M	$22.20M	$22.41M
Stock-Based Compensation	$2.21M	$2.97M	$2.92M	$2.73M	$2.24M
Investing Cash Flow	-$2.83M	$194.65M	-$2.05M	-$1.80M	$15.54M
Financing Cash Flow	-$79.49M	-$16.21M	-$18.34M	-$5.16M	-$13.03M
Share Repurchases	-$18.25M	-$15.28M	-$13.51M	-$4.77M	-$13.02M
Net Change in Cash	-$165.74M	$143.79M	-$46.31M	-$26.27M	-$40.99M

Market Snapshot

About

Opko Health is a diversified healthcare company operating in diagnostics, pharmaceuticals, and related services, with focus areas including molecular diagnostics and novel therapeutics.